Cencora (COR) Revenue — Quarter Ended Sep 30, 2023
Revenue for this reporting quarter increased compared to both the immediately preceding quarter and the same quarter one year earlier. The filing describes the company as a leading global pharmaceutical sourcing and distribution services provider.
Key takeaway
Quarter ended Sep 30, 2023 · FY2023 Q4
Revenue for this reporting quarter increased compared to both the immediately preceding quarter and the same quarter one year earlier. The filing describes the company as a leading global pharmaceutical sourcing and distribution services provider.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$68.9B
Revenue reported for this quarter.
Quarter-over-quarter
+3.0%
Change from the immediately preceding quarter.
Year-over-year
+12.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$262.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $62.8B | +5.4% |
| Mar 31, 2023 | $63.5B | +9.9% |
| Jun 30, 2023 | $66.9B | +11.5% |
| Sep 30, 2023 | $68.9B | +12.7% |
Revenue performance
The quarterly revenue continued the upward trajectory observed in earlier periods of the reporting year. The company’s broad distribution network and related services underpin its operations.
Quarterly comparison
Revenue rose sequentially from the prior quarter and also showed a year-over-year increase relative to the same quarter last year. Both comparisons reflect higher revenue levels.
What to watch
The filing references ongoing opioid litigation payments that will be made over a multi-year period, which may affect future cash flows.